The biology of castration-resistant prostate cancer

Current Problems in Cancer

Volumn 39, Issue 1, 2015, Pages 17-28

  Lian, Fei ^a   Sharma, Nitya V ^a   Moran, Josue D ^a   Moreno, Carlos S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GROWTH FACTOR; LONG UNTRANSLATED RNA; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER; WNT PROTEIN; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ARTICLE; BIOLOGY; CANCER GENETICS; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG TARGETING; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MULTIGENE FAMILY; NONHUMAN; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; EPIGENOMICS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84921838515     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2014.11.004     Document Type: Article

References (140)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Wang Q., Li W., Zhang Y., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138(2):245-256.
3. Zarour L., Alumkal J. Emerging therapies in castrate-resistant prostate cancer. Curr Urol Rep 2010, 11(3):152-158.
4. Karantanos T., Corn P.G., Thompson T.C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013, 32(49):5501-5511.
5. Enzalutamide shows strong activity in prostate cancer. Cancer Discov 2014, 4(4):OF2.
6. Agarwal N., Di Lorenzo G., Sonpavde G., Bellmunt J. New agents for prostate cancer. Ann Oncol 2014, 25(9):1700-1709.
7. Ezzell E.E., Chang K.S., George B.J. New agents in the arsenal to fight castrate-resistant prostate cancer. Curr Oncol Rep 2013, 15(3):239-248.
8. Saad F., Miller K. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens. Urol Oncol 2014, 32(2):70-79.
9. Beltran H., Beer T.M., Carducci M.A., et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 2011, 60(2):279-290.
10. Dayyani F., Gallick G.E., Logothetis C.J., Corn P.G. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011, 103(22):1665-1675.
11. Antonarakis E.S., Carducci M.A. Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer 2010, 8(1):37-46.
12. Cai C., He H.H., Chen S., et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011, 20(4):457-471.
13. Yuan X., Cai C., Chen S., Chen S., Yu Z., Balk S.P. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2013.
14. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59(11):2511-2515.
15. Guo Z., Dai B., Jiang T., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006, 10(4):309-319.
16. Sharma N.L., Massie C.E., Ramos-Montoya A., et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013, 23(1):35-47.
17. Hsieh A.C., Liu Y., Edlind M.P., et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485(7396):55-61.
18. Brenner J.C., Chinnaiyan A.M. Disruptive events in the life of prostate cancer. Cancer Cell 2011, 19(3):301-303.
19. Carver B.S., Chapinski C., Wongvipat J., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19(5):575-586.
20. Gonzalez-Billalabeitia E., Seitzer N., Song S.J., et al. Vulnerabilities of PTEN-p53-deficient prostate cancers to compound PARP/PI3K inhibition. Cancer Discov 2014, 4(8):896-904.
21. Chin Y.M., Yuan X., Balk S.P., Toker A. PTEN-deficient tumors depend on akt2 for maintenance and survival. Cancer Discov 2014, 4(8):942-955.
22. Grasso C.S., Wu Y.M., Robinson D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487(7406):239-243.
23. Hong S.W., Shin J.S., Moon J.H., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype. Apoptosis 2014, 19(5):895-904.
24. Nakabayashi M., Werner L., Courtney K.D., et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 2012, 110(11):1729-1735.
25. Templeton A.J., Dutoit V., Cathomas R., et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013, 64(1):150-158.
26. de Muga S., Hernandez S., Agell L., et al. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Mod Pathol 2010, 23(5):703-712.
27. Mimeault M., Johansson S.L., Batra S.K. Pathobiological implications of the expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One 2012, 7(2):e31919.
28. Aggarwal R.R., Ryan C.J., Chan J.M. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?. Urol Oncol 2013, 31(5):522-530.
29. Fahrenholtz C.D., Beltran P.J., Burnstein K.L. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Mol Cancer Ther 2013, 12(4):394-404.
30. Armstrong K., Ahmad I., Kalna G., et al. Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. Br J Cancer 2011, 105(9):1362-1369.
31. Mathew P., Thall P.F., Bucana C.D., et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007, 13(19):5816-5824.
32. Najy A.J., Jung Y.S., Won J.J., et al. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate 2012, 72(12):1328-1338.
33. Knudsen B.S., Gmyrek G.A., Inra J., et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002, 60(6):1113-1117.
34. Lee R.J., Smith M.R., Targeting M.E.T. and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 2013, 19(1):90-98.
35. Varkaris A., Corn P.G., Gaur S., Dayyani F., Logothetis C.J., Gallick G.E. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 2011, 20(12):1677-1684.
36. Mulholland D.J., Kobayashi N., Ruscetti M., et al. PTEN loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 2012, 72(7):1878-1889.
37. Sridhar S.S., Hotte S.J., Chin J.L., et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 2010, 33(6):609-613.
38. Whang Y.E., Armstrong A.J., Rathmell W.K., et al. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol 2013, 31(1):82-86.
39. Cathomas R., Rothermundt C., Klingbiel D., et al. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012, 18(21):6049-6057.
40. de Bono J.S., Piulats J.M., Pandha H.S., et al. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 2014, 20(7):1925-1934.
41. Margel D., Urbach D.R., Lipscombe L.L., et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013, 31(25):3069-3075.
42. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11(2):85-95.
43. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011, 11(5):325-337.
44. Giatromanolaki A., Koukourakis M.I., Koutsopoulos A., Mendrinos S., Sivridis E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther 2012, 13(13):1284-1289.
45. Altenberg B., Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84(6):1014-1020.
46. Quinn B.J., Kitagawa H., Memmott R.M., Gills J.J., Dennis P.A. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013, 24(9):469-480.
47. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648.
48. Tomlins S.A., Laxman B., Dhanasekaran S.M., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448(7153):595-599.
49. Helgeson B.E., Tomlins S.A., Shah N., et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008, 68(1):73-80.
50. Tomlins S.A., Mehra R., Rhodes D.R., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006, 66(7):3396-3400.
51. Wang X.S., Shankar S., Dhanasekaran S.M., et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov 2011, 1(1):35-43.
52. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18(1):11-22.
53. Lee W.H., Isaacs W.B., Bova G.S., Nelson W.G. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 1997, 6(6):443-450.
54. Kong D., Heath E., Chen W., et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res 2012, 4(1):14-23.
55. Wang X., Gao H., Ren L., Gu J., Zhang Y., Zhang Y. Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer. BMC Cancer 2014, 14(1):308.
56. Kirmizis A., Bartley S.M., Kuzmichev A., et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004, 18(13):1592-1605.
57. Varambally S., Dhanasekaran S.M., Zhou M., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419(6907):624-629.
58. Varambally S., Yu J., Laxman B., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8(5):393-406.
59. Bachmann I.M., Halvorsen O.J., Collett K., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Jo Clin Oncol 2006, 24(2):268-273.
60. Berger M.F., Lawrence M.S., Demichelis F., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470(7333):214-220.
61. Bradley D., Rathkopf D., Dunn R., et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009, 115(23):5541-5549.
62. Schneider B.J., Kalemkerian G.P., Bradley D., et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 2012, 30(1):249-257.
63. Rathkopf D.E., Picus J., Hussain A., et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2013, 72(3):537-544.
64. Whyte W.A., Orlando D.A., Hnisz D., et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153(2):307-319.
65. Filippakopoulos P., Qi J., Picaud S., et al. Selective inhibition of BET bromodomains. Nature 2010, 468(7327):1067-1073.
66. Chapuy B., McKeown M.R., Lin C.Y., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24(6):777-790.
67. Loven J., Hoke H.A., Lin C.Y., et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153(2):320-334.
68. Cho H., Herzka T., Zheng W., et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of PTEN-mutant metastasis. Cancer Discov 2014, 4(3):318-333.
69. Asangani I.A., Dommeti V.L., Wang X., et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014.
70. Wyce A., Ganji G., Smitheman K.N., et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One 2013, 8(8):e72967.
71. Bubendorf L., Schopfer A., Wagner U., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathol 2000, 31(5):578-583.
72. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev Cancer 2009, 9(4):265-273.
73. Zhu Z., Sanchez-Sweatman O., Huang X., et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001, 61(4):1707-1716.
74. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009, 19(2):156-172.
75. Valcourt U., Kowanetz M., Niimi H., Heldin C.H., Moustakas A. TGF-beta and the SMAD signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005, 16(4):1987-2002.
76. Tiwari N., Tiwari V.K., Waldmeier L., et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling ezh2 expression and epigenetic reprogramming. Cancer Cell 2013, 23(6):768-783.
77. Wang L., Li Y., Yang X., et al. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. Prostate 2014, 74(6):647-658.
78. Zhang J., Liang Q., Lei Y., et al. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res 2012, 72(12):4597-4608.
79. Huang Z., Hurley P.J., Simons B.W., et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget 2012, 3(6):651-663.
80. Cai C., Wang H., He H.H., et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Investig 2013, 123(3):1109-1122.
81. Thomsen M.K., Ambroisine L., Wynn S., et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 2010, 70(3):979-987.
82. Wang H., He L., Ma F., et al. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/beta-catenin activation in breast cancer. J Biol Chem 2013, 288(9):6478-6487.
83. Scharer C.D., McCabe C.D., Ali-Seyed M., Berger M.F., Bulyk M.L., Moreno C.S. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 2009, 69(2):709-717.
84. Sinner D., Kordich J.J., Spence J.R., et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007, 27(22):7802-7815.
85. Liu P., Ramachandran S., Ali Seyed M., et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006, 66(8):4011-4019.
86. Moreno C.S. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol 2010, 176(2):518-527.
87. Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nature Rev Urol 2012.
88. Zheng D., Decker K.F., Zhou T., et al. Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Mol Cancer Res 2013, 11(5):482-493.
89. Wu L., Zhao J.C., Kim J., Jin H.J., Wang C.Y., Yu J. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res 2013, 73(19):6068-6079.
90. Wang G., Wang J., Sadar M.D. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008, 68(23):9918-9927.
91. Lee E., Madar A., David G., Garabedian M.J., Dasgupta R., Logan S.K. Inhibition of androgen receptor and beta-catenin activity in prostate cancer. Proc Natl Acad Sci U S Am 2013, 110(39):15710-15715.
92. Carvalho F.L., Simons B.W., Eberhart C.G., Berman D.M. Notch signaling in prostate cancer: a moving target. Prostate 2014, 74(9):933-945.
93. Efstathiou E., Karlou M., Wen S., et al. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 2013, 73(2):153-161.
94. Gowda P.S., Deng J.D., Mishra S., et al. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression. Mol Cancer Res 2013, 11(11):1448-1461.
95. Domingo-Domenech J., Vidal S.J., Rodriguez-Bravo V., et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012, 22(3):373-388.
96. Martens-Uzunova E.S., Bottcher R., Croce C.M., Jenster G., Visakorpi T., Calin G.A. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol 2014, 65(6):1140-1151.
97. Crea F., Watahiki A., Quagliata L., et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 2014, 5(3):764-774.
98. Prensner J.R., Chinnaiyan A.M. The emergence of lncRNAs in cancer biology. Cancer Discov 2011, 1(5):391-407.
99. Cech T.R., Steitz J.A. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 2014, 157(1):77-94.
100. Geisler S., Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013, 14(11):699-712.
101. Aguilo F., Zhou M.M., Walsh M.J. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res 2011, 71(16):5365-5369.
102. Pickard M.R., Mourtada-Maarabouni M., Williams G.T. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013, 1832(10):1613-1623.
103. Prensner J.R., Iyer M.K., Sahu A., et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Gen 2013, 45(11):1392-1398.
104. Ren S., Liu Y., Xu W., et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 2013, 190(6):2278-2287.
105. Takayama K., Horie-Inoue K., Katayama S., et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J 2013, 32(12):1665-1680.
106. Wang L., Han S., Jin G., et al. Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. Int J Oncol 2014, 44(6):2041-2049.
107. Yang L., Lin C., Jin C., et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013, 500(7464):598-602.
108. Prensner J.R., Sahu A., Iyer M.K., et al. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 2014, 5(6):1434-1438.
109. Adair T.H., Montani J.P. Angiogenesis 2010, Morgan & Claypool Life Sciences, San Rafael (CA).
110. Karagiannis G.S., Saraon P., Jarvi K.A., Diamandis E.P. Proteomic signatures of angiogenesis in androgen-independent prostate cancer. Prostate 2014, 74(3):260-272.
111. Mak P., Leav I., Pursell B., et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010, 17(4):319-332.
112. Small A.C., Oh W.K. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther 2012, 12(9):1241-1249.
113. Olsson A., Bjork A., Vallon-Christersson J., Isaacs J.T., Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010, 9:107.
114. Krupitskaya Y., Wakelee H.A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009, 10(6):597-605.
115. Kelly W.K., Halabi S., Carducci M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012, 30(13):1534-1540.
116. Tannock I.F., Fizazi K., Ivanov S., et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013, 14(8):760-768.
117. Yakes F.M., Chen J., Tan J., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Therap 2011, 10(12):2298-2308.
118. Smith D.C., Smith M.R., Sweeney C., et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013, 31(4):412-419.
119. Basch E., Autio K.A., Smith M.R., et al. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol 2014, pii: S0302-2838(14)00132-8. [Epub ahead of print].
120. Nguyen H.M., Ruppender N., Zhang X., et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 2013, 8(10):e78881.
121. Crawford E.D., Stone N.N., Yu E.Y., et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology 2014, 83(3):664-669.
122. Andriole G.L., Crawford E.D., Grubb R.L., et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104(2):125-132.
123. Schroder F.H., Hugosson J., Roobol M.J., et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366(11):981-990.
124. Miller A.B. New data on prostate-cancer mortality after PSA screening. N Engl J Med 2012, 366(11):1047-1048.
125. Chou R., Croswell J.M., Dana T., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155(11):762-771.
126. Chou R., LeFevre M.L. Prostate cancer screening-the evidence, the recommendations, and the clinical implications. J Am Med Assoc 2011, 306(24):2721-2722.
127. Leyten G.H., Hessels D., Jannink S.A., et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014, 65(3):534-542.
128. Danila D.C., Anand A., Sung C.C., et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011, 60(5):897-904.
129. Martinez-Pineiro L., Schalken J.A., Cabri P., Maisonobe P., de la Taille A., Triptocare Study Group Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. BJU Int 2014, 114(4):608-616.
130. Park K., Dalton J.T., Narayanan R., et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol 2014, 32(3):206-211.
131. Qu X., Randhawa G., Friedman C., et al. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One 2013, 8(9):e74671.
132. Vaananen R.M., Lilja H., Kauko L., et al. Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens. Urology 2014, 83(2):511.e1-511.e7.
133. Yao Y., Wang H., Li B., Tang Y. Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis. Tumour Biol 2014, 35(3):2157-2166.
134. Dijkstra S., Birker I.L., Smit F.P., et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 2014, 191(4):1132-1138.
135. Irshad S., Bansal M., Castillo-Martin M., et al. A molecular signature predictive of indolent prostate cancer. Sci Transl Med 2013, 5(202):202ra122.
136. Aytes A., Mitrofanova A., Lefebvre C., et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 2014, 25(5):638-651.
137. Glinsky G.V., Glinskii A.B., Stephenson A.J., Hoffman R.M., Gerald W.L. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Investig 2004, 113(6):913-923.
138. Sboner A., Demichelis F., Calza S., et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010, 3:8.
139. Long Q., Xu J., Osunkoya A.O., et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res 2014, 74(12):3228-3237.
140. Cuzick J., Swanson G.P., Fisher G., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011, 12(3):245-255.